Abstract
The potential of Compritol®888 ATO as a release modifier to retard the release of highly water soluble drug, metoprolol succinate (MPL) was exploited. Different ratios of Compritol®888 ATO versus MPL were utilized and the effect of various formulation methods was evaluated to sustain the release of MPL. MPL: Compritol®888 ATO in 1:2 ratio could successfully retard the release of MPL. Melt granulation method “as hot process” was found to be effective when compared to direct compression and wet granulation. The in vitro release characteristics of tablets were studied in pH 6.8 phosphate buffer at 50 rpm using USP Type II apparatus. Formulation F7 retarded MPL release with ~90% release after 20h. Stability studies showed no significant difference (f2>50) in MPL release profile after three months of storage period at 25±2°C/60±5% RH and 40±2°C/75±5% RH. The bioavailability of sustained release tablets, F7 was compared with commercially available tablets, MetXL50 in 12 healthy human volunteers in a crossover design. Plasma concentration of MPL was determined using HPLC with fluorescence detector. IVIVC correlation was obtained by deconvoluting the plasma concentration-time curve using a model independent Wagner-Nelson method. Correlations of fraction of drug dissolved in vitro and fraction of drug absorbed in vivo displayed a significant linear relationship for sustained release tablets of MPL.
Keywords: Compritol®888ATO, metoprolol succinate, melt granulation, sustained release, in vitro–in vivo correlation.
Current Drug Delivery
Title:Compritol®888 ATO a Lipid Excipient for Sustained Release of Highly Water Soluble Active: Formulation, Scale-up and IVIVC Study
Volume: 10 Issue: 5
Author(s): Shilpa N. Patere, Neha S. Desai, Ankitkumar S. Jain, Prashant P. Kadam, Urmila M. Thatte, Nithya Gogtay, Chhanda J. Kapadia, Nabil Farah and Mangal S. Nagarsenker
Affiliation:
Keywords: Compritol®888ATO, metoprolol succinate, melt granulation, sustained release, in vitro–in vivo correlation.
Abstract: The potential of Compritol®888 ATO as a release modifier to retard the release of highly water soluble drug, metoprolol succinate (MPL) was exploited. Different ratios of Compritol®888 ATO versus MPL were utilized and the effect of various formulation methods was evaluated to sustain the release of MPL. MPL: Compritol®888 ATO in 1:2 ratio could successfully retard the release of MPL. Melt granulation method “as hot process” was found to be effective when compared to direct compression and wet granulation. The in vitro release characteristics of tablets were studied in pH 6.8 phosphate buffer at 50 rpm using USP Type II apparatus. Formulation F7 retarded MPL release with ~90% release after 20h. Stability studies showed no significant difference (f2>50) in MPL release profile after three months of storage period at 25±2°C/60±5% RH and 40±2°C/75±5% RH. The bioavailability of sustained release tablets, F7 was compared with commercially available tablets, MetXL50 in 12 healthy human volunteers in a crossover design. Plasma concentration of MPL was determined using HPLC with fluorescence detector. IVIVC correlation was obtained by deconvoluting the plasma concentration-time curve using a model independent Wagner-Nelson method. Correlations of fraction of drug dissolved in vitro and fraction of drug absorbed in vivo displayed a significant linear relationship for sustained release tablets of MPL.
Export Options
About this article
Cite this article as:
Patere N. Shilpa, Desai S. Neha, Jain S. Ankitkumar, Kadam P. Prashant, Thatte M. Urmila, Gogtay Nithya, Kapadia J. Chhanda, Farah Nabil and Nagarsenker S. Mangal, Compritol®888 ATO a Lipid Excipient for Sustained Release of Highly Water Soluble Active: Formulation, Scale-up and IVIVC Study, Current Drug Delivery 2013; 10 (5) . https://dx.doi.org/10.2174/1567201811310050006
DOI https://dx.doi.org/10.2174/1567201811310050006 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Clinical Problems of Hypertension Treatment in Hemodialysis Patients
Current Vascular Pharmacology Transcatheter Aortic Valve Implantation Infective Endocarditis: Current Data and Implications on Prophylaxis and Management
Current Pharmaceutical Design Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Venoms and Poisonings during the Centuries: A Narrative Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Matrix Metalloproteinases
Current Medicinal Chemistry Homocysteine and Heart Failure: An Overview
Recent Patents on Cardiovascular Drug Discovery Endothelial Changes in Individuals with Prehypertension
Current Hypertension Reviews Markers of Early Vascular Ageing
Current Pharmaceutical Design Atrial Fibrillation: Biomarkers Determining Prognosis
Current Medicinal Chemistry PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery
Current Drug Metabolism Hypereosinophilic Syndrome, Churg-Strauss Syndrome and Parasitic Diseases: Possible Links between Eosinophilia and Thrombosis
Current Vascular Pharmacology Hydrogen Sulfide and Endothelial Dysfunction: Relationship with Nitric Oxide
Current Medicinal Chemistry When Cells Become a Drug. Endothelial Progenitor Cells for Cardiovascular Therapy: Aims and Reality
Recent Patents on Cardiovascular Drug Discovery Targeting NO/cGMP Signaling in the CNS for Neurodegeneration and Alzheimer’s Disease
Current Medicinal Chemistry Editorial [Hot topic: Vitamin D Deficiency in Cardiovascular and Renal Disease: New Light Shed on an Old Enemy (Guest Editor: Martin H. de Borst)]
Current Drug Targets Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Comprehensive Analysis of SARS-COV-2 Drug Targets and Pharmacological Aspects in Treating the COVID-19
Current Molecular Pharmacology COX-2 and Colorectal Cancer
Current Pharmaceutical Design Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design On Some Physiological Aspects of Ethanol Repercussion on Neural and Cardiorenal Functions
Central Nervous System Agents in Medicinal Chemistry